Delta Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Delta Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1	Closed	-$878	–	683
2023 Q4	$878	Buy	+1	New	+$823	﹤0.01%	619
2023 Q1	–	Sell	-16	Closed	-$11.5K	–	660
2022 Q4	$11.5K	Buy	+16	New	+$11.8K	﹤0.01%	406
2020 Q1	–	Sell	-4	Closed	-$2K	–	641
2019 Q4	$2K	Hold	4	–	–	﹤0.01%	586
2019 Q3	$1K	Hold	4	–	–	﹤0.01%	597
2019 Q2	$1K	Hold	4	–	–	﹤0.01%	539
2019 Q1	$2K	Hold	4	–	–	﹤0.01%	514
2018 Q4	$1K	Hold	4	–	–	﹤0.01%	635
2018 Q3	$2K	Hold	4	–	–	﹤0.01%	616
2018 Q2	$1K	Hold	4	–	–	﹤0.01%	645
2018 Q1	$1K	Hold	4	–	–	﹤0.01%	649
2017 Q4	$2K	Hold	4	–	–	﹤0.01%	603
2017 Q3	$2K	Hold	4	–	–	﹤0.01%	579
2017 Q2	$2K	Hold	4	–	–	﹤0.01%	558
2017 Q1	$2K	Buy	+4	New	+$1.48K	﹤0.01%	572

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Delta Asset Management's REGN Position: Q1 2024 in Review

Delta Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 1 share — an estimated $878 sold.

Delta Asset Management first reported a position in REGN in Q1 2017 and held it in 14 quarters. The position peaked at $11.5K in Q4 2022. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Delta Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Delta Asset Management sold 1 Regeneron Pharmaceuticals share in Q1 2024, an estimated $878.
Delta Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 14 quarters.
Delta Asset Management's Regeneron Pharmaceuticals position peaked at $11.5K in Q4 2022.
1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Delta Asset Management's 13F filing for Q1 2024, filed 13 May 2024.